Ultragenyx Pharmaceutical
RARE
RARE
268 hedge funds and large institutions have $3.73B invested in Ultragenyx Pharmaceutical in 2024 Q1 according to their latest regulatory filings, with 53 funds opening new positions, 100 increasing their positions, 75 reducing their positions, and 20 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more call options, than puts
Call options by funds: $ | Put options by funds: $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding
Funds holding: →
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
4% less capital invested
Capital invested by funds: $3.87B → $3.73B (-$144M)
1.58% less ownership
Funds ownership: 98.64% → 97.06% (-1.6%)
Holders
268
Holding in Top 10
3
Calls
$31.5M
Puts
$16.9M
Top Buyers
| 1 | +$31.7M | |
| 2 | +$22.4M | |
| 3 | +$19.8M | |
| 4 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
+$17.2M |
| 5 |
EHI
Eagle Health Investments
Greenwich,
Connecticut
|
+$14M |
Top Sellers
| 1 | -$43M | |
| 2 | -$40.9M | |
| 3 | -$37.1M | |
| 4 |
Morgan Stanley
New York
|
-$32.2M |
| 5 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$31M |